rood blauwe elepsis logo Belegger.nl
Uitgebreid zoeken

Guru Terug naar discussie overzicht

***** GTCB 2007 ******

2.783 Posts
Pagina: «« 1 ... 76 77 78 79 80 ... 140 »» | Laatste | Omlaag ↓
  6. [verwijderd] 7 mei 2007 18:23

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    5 sterren

    This is a list of top research analysts based on the accuracy of earnings estimates on GTCB, according to StarMine. Analysts that appear here are limited to those covering GTCB for a significant period of time. Learn More.
    Total Ranked Analysts: 3

  7. [verwijderd] 7 mei 2007 18:48

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Bay State digs deep, grows up since BIO 2000
    Plastics, goats among innovation hotbeds
    Mass High Tech: The Journal of New England Technology - May 4, 2007by Lucy Caldwell-StairMass High Tech
    Print this Article Email this Article Reprints RSS Feeds Most Viewed Most Emailed
    When BIO last held its conference in Boston seven years ago, the human genome hadn't been fully sequenced, biotech stock prices were soaring, bioinformatics was brand-new, and global pharmaceutical competition hadn't heated up yet.

    While much has changed for New England biotech since BIO 2000, ingenuity still shines brilliantly here, especially in therapeutics research and development and in bioengineering, as shown in two companies who will exhibit at the conference this May in Boston.





    Millipore Corp. in Billerica is making the dream of the "plastics factory" a reality with its disposable bioprocessing equipment. Single-use plastic bags and pipes don't need to be disinfected for repeated use, trumping traditional stainless steel.

    "Over the past two years, disposables for biopharmaceuticals have really taken off," said Roberta Landon, group product manager in Millipore's Bioprocess Division. "The major driver is that they assist with speed to market," she said.

    GTC Biotherapeutics is taking production even further. The Framingham-based company manufactures human proteins in goats. Yes, a flock of goats is the newest pharmaceutical factory. Using farm animals to raise antibodies for research has become routine, but it's a completely new feat to grow human proteins in genetically engineered goats. These proteins are extracted and purified to become lifesaving drugs for patients who can't make them on their own.

    Last summer, GTC Biotherapeutics won European regulatory approval to commercialize the human anti-clotting protein it extracts from the milk of transgenic goats. It's one of many human proteins that can't be made in enough quantity using its usual method of growing live cells in vats. GTC's new technique is creating entirely new markets.

    "The key competitive advantage we have is we don't have limited production capacity, so the company can expand into therapies that require large quantities of product," said president Geoffrey Cox, recently to investors.

    Of course, New England faces stiff competition from abroad as well as from other U.S. regions. That competition will be out in force during BIO 2007 and supported by dozens of economic development groups and consortia exhibiting at the convention -- the Massachusetts Biotechnology Council says it's ready.

    A surge of startups that had begun at about the same time as BIO 2000 filled the state with companies that, in 2002, were considered "a bit like adolescents -- well beyond the infancy of their startup years, but not yet adults in the sense of being healthy, profitable companies," according to the Massachusetts Biotechnology Council in its MassBiotech 2010 report, published at about the same time.

    Since then, many of those biotechnology and life sciences companies have either folded or grown up. The investment community has certainly responded. The IPO market has once again begun to open, offering exit opportunities for those companies that were able to find funding. And more and more companies are being funded. For example, in 2000, biopharmaceutical companies in Greater Boston raised $370 million in venture capital investment, according to Dow Jones VentureOne. Last year, that number was $570 million.

    And while earlier this decade no Massachusetts pharmaceutical company had produced a blockbuster drug (more than $1 billion in sales), last year saw two companies with drugs selling in that stratosphere. At Biogen Idec, sales of Avonex generated worldwide revenue of $1.7 billion in 2006, up from sales of $1.5 billion in 2005. And Genzyme Corp. said sales of its Cerezyme drug totaled $1 billion in 2006, which represented 35 percent of all product revenue for the Cambridge company.

    If all goes according to plan at GTC Biotherapeutics, its anti-clotting drug could someday be a $500 million to $700 million drug, said Cox, its president. More drugs will follow for oncology and automimmune diseases based on growing hard-to-express proteins in transgenic mammals.

    And Millipore's disposables make it easier for Massachusetts' biotech "teenagers" to proceed through drug development, that is, "for folks in Phase 2, where you're still not sure you're going to make it through the trials," says Landon.

    Lucy Caldwell-Stair is a freelance writer in Newton

  12. [verwijderd] 7 mei 2007 21:41

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    werkelijk om ziek van te worden..De vuillakken slaan mooi in rond dit niveau en straks gaan ze weer in de verkoop zo rond de 1.20.Waar we op deze manier in 2010 nog niet doorheen gaan.

    Eindeloos...
2.783 Posts
Pagina: «« 1 ... 76 77 78 79 80 ... 140 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Belegger.nl

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.070
AB InBev 2 5.518
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.730
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 265
Accsys Technologies 23 10.747
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 191
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.753
Aedifica 3 916
Aegon 3.258 322.870
AFC Ajax 538 7.088
Affimed NV 2 6.297
ageas 5.844 109.894
Agfa-Gevaert 14 2.051
Ahold 3.538 74.340
Air France - KLM 1.025 35.057
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.042
Alfen 16 24.912
Allfunds Group 4 1.475
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 406
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.822
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 243.332
AMG 971 133.662
AMS 3 73
Amsterdam Commodities 305 6.696
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 491
Antonov 22.632 153.605
Aperam 92 15.011
Apollo Alternative Assets 1 17
Apple 5 383
Arcadis 252 8.784
Arcelor Mittal 2.033 320.741
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.326
Aroundtown SA 1 219
Arrowhead Research 5 9.745
Ascencio 1 28
ASIT biotech 2 697
ASMI 4.108 39.240
ASML 1.766 107.940
ASR Nederland 21 4.500
ATAI Life Sciences 1 7
Atenor Group 1 494
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.681
Axsome Therapeutics 1 177
Azelis Group 1 64
Azerion 7 3.403